Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance

Springer Science and Business Media LLC - Tập 12 Số 1 - 2021
Raees Tonse1, Muni Rubens2, Haley Appel1, Martin C. Tom1, Matthew D. Hall1, Yazmín Odia3, Michael W. McDermott3, Manmeet Ahluwalia3, Minesh P. Mehta1, Rupesh Kotecha3
1Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Office 1R203, Miami, FL, 33176, USA
2Office of Clinical Research, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
3Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

Tóm tắt

Abstract Background Treatment paradigms for metastatic non-small cell lung cancer are increasingly based on biomarker-driven therapies, with the most common alteration being mutation in the epidermal growth factor receptor (EGFR). Change in expression of such biomarkers could have a profound impact on the choice and efficacy of a selected targeted therapeutic, and hence the objective of this study was to analyze discordance in EGFR status in patients with lung cancer brain metastasis (LCBM). Methods Using PRISMA guidelines, a systematic review was performed of series in the Medline database of biopsied or resected LCBM published before May, 2020. Key words included “lung cancer” and “brain metastasis” combined with “epidermal growth factor receptor/EGFR,” and “receptor conversion/discordance or concordance.” Weighted random effects models were used to calculate pooled estimates. Results We identified 501 patients from 19 full-text articles for inclusion in this study. All patients underwent biopsy or resection of at least one intracranial lesion to compare to the primary tumor. On primary/LCBM comparison, the weighted pooled estimate for overall EGFR receptor discordance was 10% (95% CI 5–17%). The weighted effects model estimated a gain of an EGFR mutation in a brain metastases in patients with negative primary tumors was 7% (95% CI 4–12%). Alternatively, the weighted effects model estimate of loss of an EGFR mutation in patients with detected mutations in the primary tumor was also 7% (95% CI 4–10%). KRAS testing was also performed on both primary tumors and LCBM in a subset of 148 patients. The weighted effects estimate of KRAS-mutation discordance among LCBM compared to primary tumors was 13% (95% CI 5–27%). The weighted effects estimated of KRAS gain and loss in LCBM was 10% (95% CI 6–18%) and 8% (95% CI 4–15%), respectively. Meta-regression analysis did not find any association with any factors that could be associated with discordances. Conclusions EGFR and KRAS mutation status discordance between primary tumor and LCBM occurs in approximately 10% and 13% of patients, respectively. Evaluation of LCBM receptor status is key to biomarker-driven targeted therapy for intracranial disease and awareness of subtype switching is critical for those patients treated with systemic therapy alone for intracranial disease.

Từ khóa


Tài liệu tham khảo

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.

Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther. 2017;102:757–64. https://doi.org/10.1002/cpt.810.

Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23:6207–19. https://doi.org/10.1200/JCO.2005.03.145.

Palmer JD, et al. Multidisciplinary patient-centered management of brain metastases and future directions. Neurooncol Adv. 2020;2:vdaa034. https://doi.org/10.1093/noajnl/vdaa034.

Han G, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget. 2016;7:56998–7010. https://doi.org/10.18632/oncotarget.10933.

Hulsbergen AFC, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22:1173–81. https://doi.org/10.1093/neuonc/noaa013.

Kotecha R, et al. Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neurooncol Adv. 2021;3:vdab010. https://doi.org/10.1093/noajnl/vdab010.

Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097. https://doi.org/10.1371/journal.pmed.1000097.

Zhang Y, et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-risk of bias and indirectness. J Clin Epidemiol. 2019;111:94–104. https://doi.org/10.1016/j.jclinepi.2018.01.013.

Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2.

Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646–54. https://doi.org/10.1177/0272989X05282643.

Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3–9. https://doi.org/10.1093/annonc/mdx702.

Hong DS, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17. https://doi.org/10.1056/NEJMoa1917239.

Suh JH, et al. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17:279–99. https://doi.org/10.1038/s41571-019-0320-3.

Wang H, et al. Genes associated with increased brain metastasis risk in non-small cell lung cancer: comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036). Cancer. 2019;125:3535–44. https://doi.org/10.1002/cncr.32372.

Erickson AW, Brastianos PK, Das S. Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis. JAMA Netw Open. 2020;3: e201617. https://doi.org/10.1001/jamanetworkopen.2020.1617.

Ramalingam SS, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. https://doi.org/10.1056/NEJMoa1913662.

Ferrer I, et al. KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64. https://doi.org/10.1016/j.lungcan.2018.07.013.

Lindeman NI, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321–46. https://doi.org/10.5858/arpa.2017-0388-CP.

Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157: 103194. https://doi.org/10.1016/j.critrevonc.2020.103194.

Shih DJH, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371–7. https://doi.org/10.1038/s41588-020-0592-7.

Brastianos PK, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164–77. https://doi.org/10.1158/2159-8290.CD-15-0369.

Boire A, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol. 2019;21:571–84. https://doi.org/10.1093/neuonc/noz012.

Wang X, et al. Highly sensitive droplet digital PCR method for detection of de novo EGFR T790M mutation in patients with non-small cell lung cancer. Onco Targets Ther. 2020;13:10621–30. https://doi.org/10.2147/OTT.S267677.

Ying S, et al. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases. Cancer Biol Ther. 2019;20:562–70. https://doi.org/10.1080/15384047.2018.1538614.

Spence T, et al. Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer. J Clin Pathol. 2021;74:91–7. https://doi.org/10.1136/jclinpath-2020-206668.

Verheijen RB, et al. Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors. Cancer Chemother Pharmacol. 2021;87:269–76. https://doi.org/10.1007/s00280-021-04230-4.

Cho SJ, et al. Brain metastasis detection using machine learning: a systematic review and meta-analysis. Neuro Oncol. 2021;23:214–25. https://doi.org/10.1093/neuonc/noaa232.

Liao L, et al. Characterization of genetic alterations in brain metastases from non-small cell lung cancer. FEBS Open Bio. 2018;8:1544–52. https://doi.org/10.1002/2211-5463.12501.

Kobayashi H, et al. Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors. Oncol Lett. 2018;16:4243–52. https://doi.org/10.3892/ol.2018.9225.

Kim KM, et al. Discordance of epidermal growth factor receptor mutation between brain metastasis and primary non-small cell lung cancer. Brain Tumor Res Treat. 2019;7:137–40. https://doi.org/10.14791/btrt.2019.7.e44.

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67. https://doi.org/10.1016/0092-8674(90)90186-i.

Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell. 2003;4:4–6. https://doi.org/10.1016/s1535-6108(03)00167-3.

Klein CA. Gene expression sigantures, cancer cell evolution and metastatic progression. Cell Cycle. 2004;3:29–31.

Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1: e000060. https://doi.org/10.1136/esmoopen-2016-000060.

Matsumoto S, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119:1491–4. https://doi.org/10.1002/ijc.21940.

Italiano A, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006;17:981–5. https://doi.org/10.1093/annonc/mdl038.

Takahashi K, et al. Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells. Clin Cancer Res. 2007;13:111–20. https://doi.org/10.1158/1078-0432.CCR-06-0659.

Kalikaki A, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923–9. https://doi.org/10.1038/sj.bjc.6604629.

Gow CH, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009;20:696–702. https://doi.org/10.1093/annonc/mdn679.

Daniele L, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009;4:684–8. https://doi.org/10.1097/JTO.0b013e3181a52359.

Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer. 2010;116:2682–7. https://doi.org/10.1002/cncr.25014.

Han HS, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:380–6. https://doi.org/10.1016/j.cllc.2011.02.006.

Fang Q, Zhang L, Wang S, Ou W. Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2011;14:518–22. https://doi.org/10.3779/j.issn.1009-3419.2011.06.07.

Munfus-McCray D, et al. EGFR and KRAS mutations in metastatic lung adenocarcinomas. Hum Pathol. 2011;42:1447–53. https://doi.org/10.1016/j.humpath.2010.12.011.

Grommes C, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13:1364–9. https://doi.org/10.1093/neuonc/nor121.

Kamila WK, et al. EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report. Clin Exp Metastasis. 2013;30:1063–71. https://doi.org/10.1007/s10585-013-9603-8.

Luo D, et al. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol. 2014;35:2437–44. https://doi.org/10.1007/s13277-013-1323-9.

Quere G, et al. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer. 2016;16:210. https://doi.org/10.1186/s12885-016-2249-6.

Rau KM, et al. Discordance of mutation statuses of epidermal growth factor receptor and K-ras between primary adenocarcinoma of lung and brain metastasis. Int J Mol Sci. 2016;17:524. https://doi.org/10.3390/ijms17040524.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 12 Số 1

Thông tin tác giả